Recruited by the President and CEO with a charter to transition the company from biosimilars into novel immuno-oncology therapeutics. Responsible for multiple functional areas including Business Development, Legal, Compliance, Government Affairs, and, for pharmacy benefit reimbursed products, Commercial.Key Accomplishments• Led cross-functional deal team and closed the acquisition of Surface Oncology (SURF), which added 2 clinical stage oncology candidates • Launched YUSIMRY (bHUMIRA) into the highly competitive HUMIRA marketplace achieving target P&L performance, as well as created the partnership with the Mark Cuban Cost Plus Drug Company. • Supported the successful commercial launch of CIMERLI (interchangeable bLUCENTIS); and then initiated the divestiture process for CIMERLI to support the company’s continuing strategic transformation. • Supported the private placement of CHRS common stock (May 2023).• Led patent strategy and execution, which included drafting and prosecuting patent applications in conjunction with external counsel. • Provided counsel and support for international alliances with Formycon AG and Junshi Biosciences, which included joint steering committee membership.

Recruited by the US CEO to serve as the strategic legal and compliance business partner to ensure the successful scale-up of the company and launch of MONOFERRIC, the first US single dose iron replacement therapeutic. Responsible for legal, compliance, and government affairs.Key Accomplishments• Supported the successful launch of MONOFERRIC, which included commercial trade contracting, field sales and medical colleague training, and leading promotional review committee.• Led acquisition of privately-held Abfero Pharmaceuticals, which expanded company’s iron-mediated disease candidate pipeline; assumed post-closing responsibility for IP portfolio management, clinical trial legal support, and third-party manufacturing and supply partnerships.• Developed and implemented lobbying strategy regarding step therapy and access to medicines.

Recruited by the CEO with a charter to serve as Corporate Secretary and to lead the legal and business development functions. Responsible for legal, compliance, human resources, and quality assurance. Key Accomplishments• Led and closed sell-side business development transactions forming foundational partnerships with Takeda and Dr. Falk Pharma.• Supported Series C round of financing, including participating in non-deal road shows, and led drafting of corporate registration statement ahead of initial public offering (March 2021).• Coordinated and led intellectual property strategy, creation, and protection in partnership with external counsel and collaboration partners (Cedars-Sinai, Takeda, Dr. Falk Pharma). • Led human resources team through onset of COVID-19 pandemic restrictions, which included implementing a reduction in force and introducing week-on/week-off shifts for clinical lab personnel to mitigate potential quarantine impact while conducting medically necessary tests for physicians and patients.

Recruited by the Global Head, R&D Business Development to lead business development within Takeda’s largest therapeutic area (gastroenterology), divest non-core assets following the acquisition of Shire, and work cross-functionally to support key corporate initiatives. Managed a 7-member global team.Key Accomplishments• Led externalization activities across therapeutic areas, which included the formation of Phathom Pharmaceuticals (PHAT).• Served as Takeda’s alliance management representative in strategic partnership with Kyoto University’s Center for iPSC Research and Application.• Supported multinational patent litigation.

CHIEF COUNSEL, PEH TRANSACTIONS (2009-2018)Recruited by the Chief Counsel, Pfizer Essential Health Business Unit (PEH) to lead and provide transactional legal support for PEH projects and generalist legal support related to the development, manufacture, and commercialization of products generating ~$24B in annual revenues. • Negotiated and led M&A; exclusive license and asset purchase agreements; and asset divestitures.• Led the successful integration of acquired businesses into PEH.CHIEF COUNSEL, MERIDIAN MEDICAL TECHNOLOGIES (2015-2018)Served as General Counsel for a wholly-owned subsidiary which: (a) manufactures and commercializes pre-hospital emergency care products for commercial, government, and first responder customers including DoD, BARDA, and state and local agencies; and, (b) manufactures EpiPen. CHIEF COUNSEL, PEH R&D (2015-2018)Assigned by Chief Counsel, PEH to additional leadership responsibilities following the successful integration of Hospira and InnoPharma into the PEH Business Unit. Responsible for advising on general legal matters arising from product development, clinical research, medical affairs, and regulatory affairs.REGIONAL LEGAL LEAD, DEVELOPED ASIA (2012-2015)SENIOR CORPORATE COUNSEL, PATENTS (2009)DIRECTOR, STRATEGIC ALLIANCES (2006 – 2009)PATENT COUNSEL/PATENT AGENT (2001 – 2006)